Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT01478087
Other study ID # AMA-2011DCM Pilot Study
Secondary ID
Status Terminated
Phase N/A
First received November 7, 2011
Last updated February 12, 2013
Start date November 2011
Est. completion date June 2012

Study information

Verified date February 2013
Source Asahi Kasei Medical Co., Ltd.
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the clinical safety and feasibility of Mysorba in patients with chronic non-ischemic dilated cardiomyopathy (DCM).


Recruitment information / eligibility

Status Terminated
Enrollment 2
Est. completion date June 2012
Est. primary completion date June 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject is 18 years of age or older.

2. Subject has provided written informed consent.

3. Subject has been classified as NYHA Class II or III.

4. Subject has been diagnosed with chronic non-ischemic dilated cardiomyopathy, defined as left ventricular ejection fraction (LVEF) < 40% and left ventricular end diastolic dimensions (LVEDd) > 55 millimeters (mm) or LVEDd/BSA > 3.0 cm/m2.

5. Subject was diagnosed with non-ischemic dilated cardiomyopathy = 6 months and = 5 years prior to screening visit.

6. Subject is on stable optimal medical therapy, consisting of ACE inhibitor (or ARB), ß-blocker, and diuretic, for heart failure for at least 3 months

7. Subject and physician agree to switch subject from ACE inhibitors to ARB for the treatment duration.

Exclusion Criteria:

1. Subject has been classified as NYHA Class I or IV

2. Subject is currently pregnant, lactating, or of child-bearing potential and not taking adequate birth control as assessed by Investigator.

3. Subject is HBV, HCV or HIV positive.

4. Subject has anemia, defined as hemoglobin < 10.0 g/dL.

5. Subject has compromised renal function as reflected by a serum creatinine level >3.0 mg/dL or eGFR <30 mL/min or is currently on dialysis.

6. Subject has compromised hepatic function as measured by SGPT (ALT) or SGOT (AST) > three (3) times the upper limit of normal.

7. Subject had acute myocarditis = 3 months prior to screening visit.

8. Subject has a history of diameter stenosis >70% of at least one major coronary artery, as determined by angiography or CTA obtained within the previous 5 years.

9. Subject is on immunosuppressive or immunomodulation therapy: intravenous (IV), intramuscular (IM), or oral.

10. Subject has a history of the following pre-existing heart disease:

- myocardial infarction (MI), percutaneous coronary intervention (PCI), or coronary artery bypass graft (CABG)

- valvular heart disease requiring repair, replacement, or balloon valvuloplasty

- hypertrophic/restrictive cardiomyopathy or constrictive pericarditis

11. Subject is currently participating in, or = 6 months prior to screening visit has participated in, an investigational study of a new drug, biologic, or device.

12. Subject has left ventricular noncompaction.

13. Subject has a left ventricular assist device (LVAD).

14. Subject has received a heart transplant.

15. Subject has DCM due to any of the following:

- amyloidosis

- sarcoidosis

- connective tissue disease

- peripartum cardiomyopathy

- alcoholism

- endocrine dysfunction as the primary cause of DCM

- prior illicit drug use which the investigator feels as likely cause for the cardiomyopathy

- hereditary and familial conditions (such as genetic dilated cardiomyopathy, familial storage disease, Heredofamilial neurologic and neuromuscular diseases)

16. Subject has undergone cardiac resynchronization therapy = 6 months prior to screening visit.

17. Subject is unable to take ARB in place of ACE inhibitors.

18. Subject has a history of stroke = 3 months prior to screening visit.

19. Subject currently has severe systemic infection requiring treatment with antibiotics.

20. Subject currently has hemodynamic instability defined as systolic blood pressure < 90 mm Hg without afterload reduction, or cardiogenic shock, or the need for inotropic support or intra-aortic balloon pump.

21. Subject has previously undergone immunosuppressive or immunomodulation therapy.

22. Subject has known hypersensitivity or contraindication to heparin including history of heparin induced thrombocytopenia (HIT).

23. Subject has history of drug or alcohol abuse or is currently abusing alcohol or drugs.

24. Subject has active malignancy or tumor, or other non-cardiac medical condition, which causes life expectancy to be less than one year.

25. History of neutropenia (WBC < 3,000/mm3), coagulopathy, or thrombocytopenia (platelet count < 100,000/µL) that has not resolved or has required treatment in the past 6 months.

26. Subject weighs less than 40 kg (88 lbs).

27. Subject requires major elective procedures (AHA-defined intermediate to high risk surgery) within 6 months post-treatment.

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Mysorba
Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.

Locations

Country Name City State
United States Cleveland Clinic Cleveland Ohio
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Asahi Kasei Medical Co., Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Rate of Procedure Related Serious Adverse Events (SAE) at 30 Days Post-treatment. 30 Days Post Treatment Yes
Primary Rate of Device Related Serious Adverse Events (SAE) at 30 Days Post-treatment. 30 days post-treatment Yes
See also
  Status Clinical Trial Phase
Active, not recruiting NCT03560167 - Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation N/A
Terminated NCT00624520 - Mental Stress Reduction in Defibrillator Patients Phase 3
Completed NCT00549861 - Characterization of Irreversible Myocardial Injury in Cardiomyopathies by Contrast-enhanced CMR N/A
Terminated NCT04222101 - Association of Insulin Resistance and FGF21 on Cardiac Function in Pediatric Dilated Cardiomyopathy N/A
Not yet recruiting NCT02517814 - Vitamin D Supplementation Can Improve Heart Function in Idiopathic Cardiomyopathy N/A
Completed NCT01940081 - The Leiden Nonischemic Cardiomyopathy Study
Completed NCT01391507 - Pilot Study of COR-1 in Heart Failure Phase 2
Completed NCT01181414 - Spanish Atrial Fibrillation And Resynchronization Study Phase 4
Not yet recruiting NCT06091475 - Therapy to Maintain Remission in Dilated Cardiomyopathy N/A
Recruiting NCT03340675 - Oral Ifetroban in Subjects With Duchenne Muscular Dystrophy Phase 2
Recruiting NCT05981092 - A Study About the Natural History in Adults With BAG3 Dilated Cardiomyopathy (a Type of Heart Disease)
Not yet recruiting NCT06039072 - Clinical Observation of Long-term Cardiac Function Prognosis in Patients With PPCM Who Have Recovered Cardiac Function
Recruiting NCT03910725 - Electrophysiological Phenotyping Of Patients at Risk of Ventricular Arrhythmia and Sudden Cardiac Death
Recruiting NCT00221780 - Role of Left Ventricular Pacing Site N/A
Terminated NCT02958098 - My Research Legacy Pilot Study
Completed NCT00123071 - Variability of Ventricular Mass, Volume, & Ejection Fraction in Pediatric Cardiomyopathy Patients-Pediatric Heart Network N/A
Completed NCT00284713 - Progenitor Cell Therapy in Dilative Cardiomyopathy Phase 1/Phase 2
Completed NCT01260402 - Randomized Comparison of Endocardial Versus Epicardial - From the Coronary Sinus - Left Ventricular Pacing for Resynchronization in Heart Failure. N/A
Completed NCT04192214 - The Persistence of Autoantibody Neutralisation by BC 007 in Patients With Chronic HFrEF and Autoantibodies Against the Beta1-Adrenergic Receptor Phase 2
Recruiting NCT03040947 - MRI Sequence and Imaging Protocol Development